Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
Add more filters










Publication year range
1.
Adv Sci (Weinh) ; 11(20): e2307852, 2024 May.
Article in English | MEDLINE | ID: mdl-38477561

ABSTRACT

First-line treatment of multiple myeloma, a prevalent blood cancer lacking a cure, using anti-CD38 daratumumab antibody and lenalidomide is often inadequate due to relapse and severe side effects. To enhance drug safety and efficacy, an antibody-drug conjugate, TE-1146, comprising six lenalidomide drug molecules site-specifically conjugated to a reconfigured daratumumab to deliver cytotoxic lenalidomide to tumor cells is developed. TE-1146 is prepared using the HighDAR platform, which employs i) a maleimide-containing "multi-arm linker" to conjugate multiple drug molecules creating a drug bundle, and ii) a designed peptide with a Zn2+-binding cysteine at the C-termini of a reconfigured daratumumab for site-specific drug bundle conjugation. It is shown that TE-1146 remains intact and effectively enters CD38-expressing tumor cells, releasing lenalidomide, leading to enhanced cell-killing effects compared to lenalidomide/daratumumab alone or their combination. This reveals the remarkable potency of lenalidomide once internalized by myeloma cells. TE-1146 precisely delivers lenalidomide to target CD38-overexpressing tumor cells. In contrast, lenalidomide without daratumumab cannot easily enter cells, whereas daratumumab without lenalidomide relies on Fc-dependent effector functions to kill tumor cells.


Subject(s)
Antibodies, Monoclonal , Immunoconjugates , Lenalidomide , Multiple Myeloma , Multiple Myeloma/drug therapy , Humans , Immunoconjugates/pharmacology , Immunoconjugates/chemistry , Lenalidomide/pharmacology , Lenalidomide/therapeutic use , Antibodies, Monoclonal/pharmacology , Cell Line, Tumor , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Mice , Animals , Disease Models, Animal
2.
J Med Chem ; 66(15): 10604-10616, 2023 08 10.
Article in English | MEDLINE | ID: mdl-37462154

ABSTRACT

Antibodies conjugated with diagnostic/therapeutic radionuclides are attractive options for inoperable cancers lacking accurate imaging methods and effective therapeutics, such as pancreatic cancer. Hence, we have produced an antibody radionuclide conjugate termed TE-1132 comprising a α-CA19-9 scFv-Fc that is site-specifically conjugated at each C-terminus to 3 DOTA chelators via a cysteine-containing peptide linker. The smaller scFv-Fc size facilitates diffusivity within solid tumors, whereas the chelator-to-antibody ratio of six enabled 177Lu-radiolabeled TE-1132 to exhibit high radioactivity up to 520 MBq/nmol. In mice bearing BxPC3 tumors, immuno-SPECT/CT imaging of [111In]In-TE-1132 and the biodistribution of [177Lu]Lu-TE-1132 showed selective tumor accumulation. Single and multiple doses of [177Lu]Lu-TE-1132 effectively inhibited the BxPC3 tumor growth and prolonged the survival of mice with no irreversible body weight loss or hematopoietic damage. The adequate pharmacokinetic parameters, prominent tumor accumulation, and efficacy with good safety in mice encourage the further investigation of theranostic TE-1132 for treating pancreatic cancer.


Subject(s)
Immunoconjugates , Pancreatic Neoplasms , Mice , Animals , Chelating Agents , CA-19-9 Antigen , Tissue Distribution , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/drug therapy , Radiopharmaceuticals/pharmacokinetics , Cell Line, Tumor , Lutetium , Pancreatic Neoplasms
3.
J Exp Med ; 219(9)2022 09 05.
Article in English | MEDLINE | ID: mdl-35833912

ABSTRACT

Anti-interferon (IFN)-γ autoantibodies (AIGAs) are a pathogenic factor in late-onset immunodeficiency with disseminated mycobacterial and other opportunistic infections. AIGAs block IFN-γ function, but their effects on IFN-γ signaling are unknown. Using a single-cell capture method, we isolated 19 IFN-γ-reactive monoclonal antibodies (mAbs) from patients with AIGAs. All displayed high-affinity (KD < 10-9 M) binding to IFN-γ, but only eight neutralized IFN-γ-STAT1 signaling and HLA-DR expression. Signal blockade and binding affinity were correlated and attributed to somatic hypermutations. Cross-competition assays identified three nonoverlapping binding sites (I-III) for AIGAs on IFN-γ. We found that site I mAb neutralized IFN-γ by blocking its binding to IFN-γR1. Site II and III mAbs bound the receptor-bound IFN-γ on the cell surface, abolishing IFN-γR1-IFN-γR2 heterodimerization and preventing downstream signaling. Site III mAbs mediated antibody-dependent cellular cytotoxicity, probably through antibody-IFN-γ complexes on cells. Pathogenic AIGAs underlie mycobacterial infections by the dual blockade of IFN-γ signaling and by eliminating IFN-γ-responsive cells.


Subject(s)
Mycobacterium Infections , Receptors, Interferon , Antibodies, Monoclonal , Autoantibodies , Electric Impedance , Humans , Interferon-gamma , Mycobacterium Infections/genetics , Mycobacterium Infections/microbiology , Receptors, Interferon/genetics
4.
Sci Rep ; 8(1): 11548, 2018 08 01.
Article in English | MEDLINE | ID: mdl-30069035

ABSTRACT

Immunoglobulin E (IgE) antibodies play a central role in the allergic response: interaction with FcεRI on mast cells and basophils leads to immediate hypersensitivity reactions upon allergen challenge, while interaction with CD23/FcεRII, expressed on a variety of cells, regulates IgE synthesis among other activities. The receptor-binding IgE-Fc region has recently been found to display remarkable flexibility, from acutely bent to extended conformations, with allosteric communication between the distant FcεRI and CD23 binding sites. We report the structure of an anti-IgE antibody Fab (8D6) bound to IgE-Fc through a mixed protein-carbohydrate epitope, revealing further flexibility and a novel extended conformation with potential relevance to that of membrane-bound IgE in the B cell receptor for antigen. Unlike the earlier, clinically approved anti-IgE antibody omalizumab, 8D6 inhibits binding to FcεRI but not CD23; the structure reveals how this discrimination is achieved through both orthosteric and allosteric mechanisms, supporting therapeutic strategies that retain the benefits of CD23 binding.


Subject(s)
Antibodies, Anti-Idiotypic/chemistry , Antibodies, Anti-Idiotypic/metabolism , Immunoglobulin E/chemistry , Immunoglobulin E/metabolism , Receptors, IgE/metabolism , B-Lymphocytes/immunology , Crystallography, X-Ray , HEK293 Cells , Humans , Immunoglobulin Fab Fragments/chemistry , Immunoglobulin Fab Fragments/metabolism , Immunoglobulin Fc Fragments/chemistry , Immunoglobulin Fc Fragments/metabolism , Mast Cells/immunology , Protein Binding , Protein Conformation
5.
Mol Pharm ; 14(11): 4113-4120, 2017 11 06.
Article in English | MEDLINE | ID: mdl-28954509

ABSTRACT

Therapeutics reducing bone turnover, such as denosumab (Dmab), an anti-RANKL antibody, can provide treatments for patients with bone destruction. However, some patients with osteoporosis or localized primary bone tumors and many patients with various types of bone-metastatic cancer display unsatisfactory responses to Dmab. For achieving greater efficiency of RANKL neutralization in the bone microenvironment by enhancing the distribution of Dmab to the bone, we reengineered Dmab by fusing with single-chain variable fragments of an antibody specific for osteonectin (On), which is abundantly expressed in osseous tissues. The bispecific antibody, Dmab-FvOn, showed a similar activity as Dmab in inhibiting RANKL as examined in an osteoclast differentiation assay. When administered to mice, Dmab-FvOn was found to localize in increased proportions at the endosteum of the bone where osteonectin is abundant. Our study suggests that by linking anti-RANKL with an osteonectin-targeting moiety, a greater proportion of the therapeutic effector can be distributed in the bone. Future studies are needed to investigate whether the bispecific antibody can achieve higher therapeutic efficacy and lower toxicity.


Subject(s)
Osteonectin/metabolism , RANK Ligand/metabolism , Animals , Antibodies, Bispecific/immunology , Antibodies, Bispecific/metabolism , Cell Differentiation/drug effects , Denosumab/pharmacology , Mice , Osteoclasts/drug effects , Osteoclasts/metabolism , Osteonectin/immunology , RANK Ligand/immunology
6.
Acta Biotheor ; 65(2): 117-134, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28342137

ABSTRACT

The Hygiene Hypothesis has been recognized as an important cornerstone to explain the sudden increase in the prevalence of asthma and allergic diseases in modernized culture. The recent epidemic of allergic diseases is in contrast with the gradual implementation of Homo sapiens sapiens to the present-day forms of civilization. This civilization forms a gradual process with cumulative effects on the human immune system, which co-developed with parasitic and commensal Helminths. The clinical manifestation of this epidemic, however, became only visible in the second half of the twentieth century. In order to explain these clinical effects in terms of the underlying IgE-mediated reactions to innocuous environmental antigens, the low biodiversity of antigens in the domestic environment plays a pivotal role. The skewing of antigen exposure as a cumulative effect of reducing biodiversity in the immediate human environment as well as in changing food habits, provides a sufficient and parsimonious explanation for the rise in allergic diseases in a highly developed and helminth-free modernized culture. Socio-economic tendencies that incline towards a further reduction of environmental biodiversity may provide serious concern for future health. This article explains that the "Hygiene Hypothesis", the "Old Friends Hypothesis", and the "Skewed Antigen Exposure Hypothesis" are required to more fully explain the rise of allergy in modern societies.


Subject(s)
Asthma , Hygiene Hypothesis , Environment , Humans , Hypersensitivity , Immune System
7.
J Allergy Clin Immunol ; 139(4): 1195-1204.e11, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27658758

ABSTRACT

BACKGROUND: Chronic rhinosinusitis with nasal polyps is associated with local immunoglobulin hyperproduction and the presence of IgE antibodies against Staphylococcus aureus enterotoxins (SAEs). Aspirin-exacerbated respiratory disease is a severe form of chronic rhinosinusitis with nasal polyps in which nearly all patients express anti-SAEs. OBJECTIVES: We aimed to understand antibodies reactive to SAEs and determine whether they recognize SAEs through their complementarity-determining regions (CDRs) or framework regions. METHODS: Labeled staphylococcal enterotoxin (SE) A, SED, and SEE were used to isolate single SAE-specific B cells from the nasal polyps of 3 patients with aspirin-exacerbated respiratory disease by using fluorescence-activated cell sorting. Recombinant antibodies with "matched" heavy and light chains were cloned as IgG1, and those of high affinity for specific SAEs, assayed by means of ELISA and surface plasmon resonance, were recloned as IgE and antigen-binding fragments. IgE activities were tested in basophil degranulation assays. RESULTS: Thirty-seven SAE-specific, IgG- or IgA-expressing B cells were isolated and yielded 6 anti-SAE clones, 2 each for SEA, SED, and SEE. Competition binding assays revealed that the anti-SEE antibodies recognize nonoverlapping epitopes in SEE. Unexpectedly, each anti-SEE mediated SEE-induced basophil degranulation, and IgG1 or antigen-binding fragments of each anti-SEE enhanced degranulation by the other anti-SEE. CONCLUSIONS: SEEs can activate basophils by simultaneously binding as antigens in the conventional manner to CDRs and as superantigens to framework regions of anti-SEE IgE in anti-SEE IgE-FcεRI complexes. Anti-SEE IgG1s can enhance the activity of anti-SEE IgEs as conventional antibodies through CDRs or simultaneously as conventional antibodies and as "superantibodies" through CDRs and framework regions to SEEs in SEE-anti-SEE IgE-FcεRI complexes.


Subject(s)
Enterotoxins/immunology , Nasal Polyps/immunology , Rhinitis/immunology , Sinusitis/immunology , Asthma, Aspirin-Induced/immunology , Basophil Degranulation Test , Basophils/immunology , Cell Separation , Chronic Disease , Complementarity Determining Regions , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Humans , Immunoglobulin E/immunology , Immunoglobulin G/immunology , Male , Middle Aged , Staphylococcus aureus/immunology , Superantigens/immunology , Surface Plasmon Resonance
8.
Pediatr Allergy Immunol ; 27(5): 446-51, 2016 08.
Article in English | MEDLINE | ID: mdl-27090058

ABSTRACT

Targeting the IgE pathway is a clinically validated strategy for treating IgE-mediated diseases. Omalizumab, an anti-IgE antibody, which binds to free IgE and prevents the binding of IgE to FcεRI on mast cells and basophils has been approved for severe persistent allergic asthma and chronic spontaneous (idiopathic) urticaria. The therapeutic efficacy of anti-IgE has also been reported in allergic rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, anaphylaxis, and others. Anti-CεmX, which binds to membrane-bound IgE (mIgE) on IgE-switched B cells, lyses mIgE-expressing B lymphoblasts and prevents the allergen-induced generation of IgE-producing plasma cells, offers an alternative mechanism of intervening with the IgE inflammatory pathway. Because anti-CεmX does not bind to free IgE, it can modulate the IgE pathway regardless of the serum IgE levels in treated patients. These unique pharmacologic mechanisms potentially enable anti-CεmX to provide different clinical utilities from anti-IgE and serve as a therapeutic and a prophylactic in some IgE-mediated diseases, which are not adequately treated with current medicine.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Asthma/drug therapy , B-Lymphocytes/metabolism , Immunoglobulin E/metabolism , Omalizumab/therapeutic use , Rhinitis, Allergic/drug therapy , Urticaria/drug therapy , Animals , Antibody-Dependent Cell Cytotoxicity , B-Lymphocytes/immunology , Humans , Immunoglobulin E/immunology , Immunosuppression Therapy , Lymphocyte Depletion
9.
Sci Rep ; 5: 11581, 2015 Jun 26.
Article in English | MEDLINE | ID: mdl-26113483

ABSTRACT

Omalizumab, an anti-IgE antibody, used to treat severe allergic asthma and chronic idiopathic urticaria, binds to IgE in blood or membrane-bound on B lymphocytes but not to IgE bound to its high (FcεRI) or low (CD23) affinity receptor. Mutagenesis studies indicate overlapping FcεRI and omalizumab-binding sites in the Cε3 domain, but crystallographic studies show FcεRI and CD23-binding sites that are far apart, so how can omalizumab block IgE from binding both receptors? We report a 2.42-Šomalizumab-Fab structure, a docked IgE-Fc/omalizumab-Fab structure consistent with available experimental data, and the free energy contributions of IgE residues to binding omalizumab, CD23, and FcεRI. These results provide a structural and physical basis as to why omalizumab cannot bind receptor-bound IgE and why omalizumab-bound IgE cannot bind to CD23/FcεRI. They reveal the key IgE residues and their roles in binding omalizumab, CD23, and FcεRI.


Subject(s)
Antibodies, Anti-Idiotypic/chemistry , Immunoglobulin E/chemistry , Omalizumab/chemistry , Amino Acid Sequence , Anti-Asthmatic Agents/immunology , Anti-Asthmatic Agents/metabolism , Anti-Asthmatic Agents/therapeutic use , Antibodies, Anti-Idiotypic/metabolism , Antibodies, Anti-Idiotypic/therapeutic use , Asthma/drug therapy , Asthma/immunology , Binding Sites/genetics , Crystallography, X-Ray , Humans , Immunoglobulin E/metabolism , Models, Molecular , Mutation , Omalizumab/metabolism , Omalizumab/therapeutic use , Protein Binding , Protein Structure, Tertiary , Receptors, IgE/chemistry , Receptors, IgE/metabolism
10.
J Allergy Clin Immunol ; 135(2): 337-42, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24948369

ABSTRACT

In patients given a diagnosis of chronic spontaneous urticaria (CSU), there are no obvious external triggers, and the factors that initiate the clinical symptoms of wheal, flare, and itch arise from within the patient. Most patients with CSU have an autoimmune cause: some patients produce IgE autoantibodies against autoantigens, such as thyroperoxidase or double-stranded DNA, whereas other patients make IgG autoantibodies against FcεRI, IgE, or both, which might chronically activate mast cells and basophils. In the remainder of patients with CSU, the nature of the abnormalities has not yet been identified. Accumulating evidence has shown that IgE, by binding to FcεRI on mast cells without FcεRI cross-linking, can promote the proliferation and survival of mast cells and thus maintain and expand the pool of mast cells. IgE and FcεRI engagement can also decrease the release threshold of mast cells and increase their sensitivity to various stimuli through either FcεRI or other receptors for the degranulation process. Furthermore, IgE-FcεRI engagement potentiates the ability of mast cells to store and synthesize de novo inflammatory mediators and cytokines. Administration of omalizumab, by virtue of its ability to deplete IgE, attenuates the multiple effects of IgE to maintain and enhance mast cell activities and hence reduces the ability of mast cells to manifest inflammatory mechanisms in patients with CSU.


Subject(s)
Anti-Allergic Agents/pharmacology , Anti-Allergic Agents/therapeutic use , Antibodies, Anti-Idiotypic/pharmacology , Antibodies, Anti-Idiotypic/therapeutic use , Antibodies, Monoclonal, Humanized/pharmacology , Antibodies, Monoclonal, Humanized/therapeutic use , Urticaria/drug therapy , Allergens/immunology , Autoimmunity , Cell Degranulation/immunology , Chronic Disease , Histamine Release/immunology , Humans , Immunoglobulin E/immunology , Mast Cells/drug effects , Mast Cells/immunology , Mast Cells/metabolism , Omalizumab , Treatment Outcome , Urticaria/immunology , Urticaria/metabolism
11.
Pediatr Allergy Immunol ; 25(8): 733-9, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25378142

ABSTRACT

Industrial development has advanced at a varying pace in different parts of the world over the past 200 years. Inhabitants of the most industrially advanced regions have experienced major changes in patterns of antigen exposure to infectious agents and to environmental biologic substances. This article analyzes the major factors that affect the amounts and variety of antigens to which the immune system of a young child is exposed. Depending on individual living environments and lifestyles, the types of antigen exposure of young children are graded into five patterns: 'primitive', 'pre-modern', 'early modern', 'modern', and 'ultramodern'. These patterns represent increasing deviation from the pattern of human immune system exposure to antigens prior to the industrial revolution. This article further discusses how such changes in antigen exposure have affected the immunologic system, especially with regard to the development of total IgE and allergic response-relevant antigen-specific IgE, and how the patterns of antigen exposure are related to the propensity to develop allergy.


Subject(s)
Hypersensitivity/epidemiology , Infections/epidemiology , Allergens/adverse effects , Allergens/immunology , Animals , Antigens/immunology , Biological Products/adverse effects , Biological Products/immunology , Child , Environmental Exposure/adverse effects , Humans , Hypersensitivity/etiology , Hypersensitivity/immunology , Immunoglobulin E/blood , Industry , Infections/complications , Infections/immunology , Prevalence , Taiwan
12.
Nat Commun ; 5: 3139, 2014.
Article in English | MEDLINE | ID: mdl-24457896

ABSTRACT

IgE mediates hypersensitivity reactions responsible for most allergic diseases, which affect 20-40% of the population in developed countries. A 52-residue domain of membrane-bound IgE (mIgE) called CεmX is currently a target for developing therapeutic antibodies; however, its structure is unknown. Here we show that two antibodies with therapeutic potential in IgE-mediated allergic diseases, which can cause cytolytic effects on mIgE-expressing B lymphocytes and downregulate IgE production, target different conformations of an intrinsically disordered region (IDR) in the extracellular CεmX domain. We provide an important example of antibodies targeting an extracellular IDR of a receptor on the surface of intended target cells. We also provide fundamental structural characteristics unique to human mIgE, which may stimulate further studies to investigate whether other monoclonal antibodies (mAbs) targeting intrinsically disordered peptide segments or vaccine-like products targeting IDRs of a membrane protein can be developed.


Subject(s)
Immunoglobulin E/immunology , Amino Acid Sequence , Binding Sites, Antibody , Cell Membrane/immunology , Crystallography, X-Ray , Humans , Immunoglobulin E/chemistry , Models, Molecular , Molecular Dynamics Simulation , Molecular Sequence Data , Protein Conformation
13.
Mol Immunol ; 53(3): 187-97, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22944457

ABSTRACT

Surface IgD and IgM doubly positive cells comprise the major population of B cells in the human immune system. The heavy chain of membrane-bound IgD (mδ) differs from that of IgD (δ) in that mδ contains a C-terminal membrane-anchor peptide. Our group previously proposed that the N-terminal extracellular segment of 27 aa residues of the membrane-anchor peptide of mδ, referred to as the mIg isotype-specific-δ (migis-δ) segment, may provide a unique antigenic site for isotype-specific targeting of mIgD(+) B cells. Here we report the preparation of mouse mAbs specific for human migis-δ. The mAbs bound to human migis-δ-containing recombinant proteins in an ELISA and to mIgD-expressing transfectants of a CHO cell line as analyzed by flow cytometry. MAb 20E6, which binds to an epitope toward the N-terminal of human migis-δ, could stain human B cell line MC116, which expressed mIgD and mIgM. MC116 cells could be induced to undergo apoptosis by treatment with 20E6 in the presence of a second crosslinking antibody. Chimeric 20E6 caused antibody-dependent cellular cytotoxicity of MC116 cells in the presence of human PBMCs as the source of effector cells. In cultures of PBMCs, 20E6 down-regulated the population of mIgD(+) B cells. The production of human IgM by transplanted MC116 cells in NOD-SCID (NOD.CB17-Prkdc(scid)/IcrCrlBltw) mice could be suppressed by 20E6. These results encourage further investigation of the potential of anti-migis-δ mAbs to control mIgD(+) B cells, when such a manipulation may alleviate a disease state.


Subject(s)
Antibodies, Anti-Idiotypic/immunology , Antibodies, Monoclonal, Murine-Derived/immunology , B-Lymphocytes/immunology , Immunoglobulin D/metabolism , Amino Acid Sequence , Animals , Antibody-Dependent Cell Cytotoxicity , Apoptosis/immunology , B-Lymphocytes/cytology , B-Lymphocytes/transplantation , CHO Cells , Cell Line , Cricetinae , Cricetulus , Epitopes, B-Lymphocyte/genetics , Humans , Immunoglobulin D/genetics , Immunoglobulin M/genetics , Immunoglobulin M/metabolism , Immunoglobulin delta-Chains/genetics , Immunoglobulin delta-Chains/immunology , Mice , Mice, Inbred NOD , Mice, SCID , Molecular Sequence Data , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Surface Plasmon Resonance , Transplantation, Heterologous
14.
Mol Immunol ; 52(3-4): 190-9, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22706073

ABSTRACT

Type-I hypersensitivity reactions play a critical role in the pathogenesis of various allergic diseases. The successful development of the anti-IgE antibody, omalizumab, has validated IgE as an effective therapeutic target for the treatment of various IgE-mediated allergic diseases. Two research groups have reported that mAbs specific for certain parts of CɛmX, a domain of 52 aa residues in human membrane-bound IgE (mIgE), can cause the lysis of mIgE-B cells by apoptosis and antibody-dependent cellular cytotoxicity (ADCC). Herein, we explore virus-like particles formed by hepatitis B virus core antigen (HBcAg) that harbors the entire CɛmX peptide or its fragments as immunogens for inducing anti-CɛmX antibodies. The results showed that mice immunized subcutaneously with these immunogens produced antibodies that bind to recombinant CɛmX-containing human IgE.Fc in ELISA and Western blot analyses, and to genetically engineered human mIgE-expressing Ramos B cell line in fluorescence flow cytometric assays. The IgG antibodies purified from the sera of immunized mice were able to cause the apoptosis of mIgE-expressing Ramos cells through a BCR-dependent caspase pathway. Furthermore, the IgG could mediate ADCC in human mIgE-expressing A20 murine B-cell lymphoma. These studies suggest that HBcAg-CɛmX peptide immunogens warrant further investigation as a therapeutic modality for modulating IgE in patients with IgE-mediated allergic diseases.


Subject(s)
Antibodies, Anti-Idiotypic/immunology , Apoptosis , B-Lymphocytes/immunology , Hepatitis B Core Antigens/immunology , Immunoglobulin E/immunology , Vaccines, Virus-Like Particle/immunology , Animals , Antibodies, Monoclonal/immunology , Antibody-Dependent Cell Cytotoxicity , B-Lymphocytes/metabolism , Cell Line, Tumor , Down-Regulation , Female , Hepatitis B virus/immunology , Humans , Immunoglobulin E/chemistry , Lymphocyte Activation , Mice , Mice, Inbred BALB C , Peptides/chemistry , Peptides/immunology , Receptors, Antigen, B-Cell/immunology
15.
Immunobiology ; 217(7): 676-83, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22226669

ABSTRACT

A new monoclonal antibody (mAb), specific for human IgE, the central mediator of immediate-type hypersensitivity reactions, has been shown to possess a unique set of binding specificities. The mAb, 8D6, binds to a conformational epitope on the CH3 domain of human e immunoglobulin and can compete with omalizumab for binding to IgE. Like omalizumab, it does not bind to IgE bound by the high-affinity IgE.Fc receptor (FcɛRI) on basophils and mast cells. It also does not cause activation and degranulation of IgE-pulsed, human FcɛRI-expressing rat basophilic leukemic cells (RBL SX-38). The mAb can inhibit IgE binding to recombinant α chain of human FcɛRI in ELISA and to human FcɛRI-expressing RBL SX38 cells in fluorescence flow cytometric analysis. However, unlike omalizumab, 8D6 can bind to IgE already bound by the low-affinity IgE.Fc receptors (FcɛRII, or CD23), as revealed in ELISA with recombinant CD23 and in flow cytometric analysis with human B cells. Since earlier investigators have shown that anti-CD23 mAbs can inhibit the synthesis of IgE in lymphocyte culture in vitro and can down-regulate IgE production in treated patients, 8D6 may offer pharmacological mechanisms in addition to those mediated by omalizumab, for controlling IgE in patients with allergic diseases.


Subject(s)
Antibodies, Anti-Idiotypic/immunology , Antibodies, Monoclonal/immunology , Hypersensitivity, Immediate/immunology , Immunoglobulin E/immunology , Receptors, IgE/immunology , Animals , Antibodies, Anti-Idiotypic/metabolism , Antibodies, Anti-Idiotypic/pharmacology , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized/immunology , Antibodies, Monoclonal, Humanized/metabolism , Antibodies, Monoclonal, Humanized/pharmacology , Antibody Specificity , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Basophils/drug effects , Basophils/immunology , Basophils/metabolism , Binding, Competitive , Enzyme-Linked Immunosorbent Assay , Epitopes , Humans , Hypersensitivity, Immediate/drug therapy , Hypersensitivity, Immediate/metabolism , Immunoglobulin E/metabolism , Mast Cells/drug effects , Mast Cells/immunology , Mast Cells/metabolism , Mice , Mice, Inbred BALB C , Omalizumab , Protein Binding , Protein Structure, Tertiary , Rats , Receptors, IgE/metabolism
16.
Immunogenetics ; 64(4): 279-87, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22068888

ABSTRACT

Membrane-bound IgE (mIgE) on B lymphocytes is essential for IgE production. Earlier studies showed that the ε chain of mIgE (mε) on human B cells has a "long" isoform, with an extra "CεmX" domain of 52 amino acid (aa) residues between the CH4 domain and the membrane-anchor segment, as compared to the conventional "short" isoform. Because CεmX provides an antigenic site for targeting IgE-expressing B cells to down-regulate IgE production in patients with allergy, analysis of CεmX in various animals is of great interest. Hence, we analyzed the ε Ig gene, in particular, its membrane exon regions encoding the membrane anchor peptide segment and CεmX domain, of 26 species of the order Primates and 12 species of seven non-Primate orders using data obtained experimentally or retrieved from GenBank. Our analyses reveal the unexpected finding that the genes of three extant tarsier species do not contain the membrane exons for mIgE. Another striking finding is that early evolved Strepsirhini primates such as lemurs and lorises do not have gene segments for the long isoform, whereas New World monkeys such as marmosets and squirrel monkeys allow the transcription of only the long isoform. In Old World monkeys and apes, including humans, the ε gene allows the transcription of both isoforms. This work thus reveals the dramatic differences in the gene segment encoding the mε C terminal region among the four major primate lineages: the Strepsirhini primates, the tarsiers, New World monkeys, and Old World monkeys and apes/humans.


Subject(s)
Evolution, Molecular , Genetic Variation , Immunoglobulin E/genetics , Primates/genetics , Amino Acid Sequence , Animals , Base Sequence , Genomic Library , Humans , Molecular Sequence Data , Phylogeny , Primates/classification , Sequence Analysis, DNA , Sequence Homology, Amino Acid , Sequence Homology, Nucleic Acid , Species Specificity
17.
Mol Immunol ; 48(15-16): 1975-82, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21723611

ABSTRACT

Membrane-bound IgA (mIgA) is associated with Igα/Igß as the B cell receptor (BCR) complex on mIgA-expressing B cells. The α chain of mIgA (mα) contains a C-terminal membrane-anchor peptide, which encompasses extracellular, transmembrane and intracellular segments. The extracellular segment, referred to as the mIg isotype-specific (migis-α) segment or the extracellular membrane proximal domain of mα, has been proposed to be a specific antigenic site suitable for isotype-specific targeting of mIgA-expressing B cells by antibodies. In this study, we developed several anti-migis-α monoclonal antibodies (mAbs), such as mAb 29C11, specific to a segment towards the N-terminus of the 26 amino acid long migis-α. The mAbs bound strongly to synthetic peptides of migis-α and to various recombinant proteins containing migis-α as revealed by ELISA. On B cells, however, flow cytometric analysis suggested that these mAbs did not bind strongly to mIgA. After lipid rafts of B cells were disrupted by cholesterol extraction, the mAbs were able to bind strongly to the treated B cells. Moreover, immunoprecipitation analysis of these mAbs indicated that mIgA could only be pulled down by the mAbs when mIgA-expressing B cells were solubilized by strong detergents, such as sodium dodecyl sulfate (SDS), or when lipid rafts were disrupted. Together, these results suggest that the migis-α region of mIgA in the BCR is associated with lipid rafts, which hinder binding of migis-α-specific antibodies to mIgA on the cell surface. Further studies are in progress to evaluate the suitability of 29C11 or its affinity-improved variants for targeting mIgA-expressing B cells.


Subject(s)
Antibodies, Monoclonal/immunology , CD79 Antigens/immunology , Immunoglobulin A/immunology , Membrane Microdomains/immunology , Amino Acid Sequence , Antibodies, Monoclonal/metabolism , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Blotting, Western , CD79 Antigens/metabolism , Cell Line , Cell Separation , Enzyme-Linked Immunosorbent Assay , Epitope Mapping , Flow Cytometry , Humans , Immunoglobulin A/metabolism , Immunoglobulin Isotypes/immunology , Immunoglobulin Isotypes/metabolism , Immunoprecipitation , Membrane Microdomains/metabolism , Molecular Sequence Data , Protein Binding , Receptors, Antigen, B-Cell/immunology , Receptors, Antigen, B-Cell/metabolism , Recombinant Proteins/immunology
18.
Immunogenetics ; 62(5): 273-80, 2010 May.
Article in English | MEDLINE | ID: mdl-20333376

ABSTRACT

The epsilon chain of membrane-bound IgE (mIgE) is expressed predominantly as a "long" isoform, containing an extra segment of 52 amino acid (a.a.) residues, referred to as C epsilon mX, between the CH4 domain and the C-terminal membrane-anchoring transmembrane peptide. C epsilon mX results from an alternative splicing of the epsilon RNA transcript at 156-bp upstream of the splicing acceptor site used by the "short" isoform. Here, based on an analysis of the C epsilon mX genomic DNA sequences of 320 subjects residing in Taiwan, we report that single-nucleotide polymorphisms have been found at two positions, namely, G/T at #46 and A/G at #93 (along the 156 bp of C epsilon mX), with the former creating an amino acid change from Val to Leu at #16 (along the 52 a.a. of C epsilon mX) and the latter resulting in no change (Gly). Among the 640 C epsilon mX sequences identified, the previously known 46G93A allelic form appeared 293 times, the newly discovered 46T93A allelic form (GeneBank accession no. GU208817) 26 times, and the 46G93G allelic form (GU208818) 321 times. No 46T93G allelic form was found. Serum IgE measurements showed that the polymorphisms did not correlate with the levels of serum IgE. The anti-C epsilon mX monoclonal antibody, 4B12, could bind equally well to mIgE.Fc(L)(16V) and mIgE.Fc(L)(16L). While genetic variation of C epsilon mX of broader populations should also be investigated, these newly discovered genetic variants of C epsilon mX in the Taiwanese population do not seem to affect the feasibility of using an anti-C epsilon mX mAb, such as 4B12, to target mIgE-expressing B cells.


Subject(s)
Asthma/genetics , Asthma/immunology , Immunoglobulin E/chemistry , Immunoglobulin E/genetics , Polymorphism, Single Nucleotide , Adolescent , Adult , Amino Acid Sequence , Base Sequence , Female , Humans , Male , Middle Aged , Molecular Sequence Data , Protein Structure, Tertiary , Taiwan , Young Adult
19.
Int Immunopharmacol ; 10(4): 533-9, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20139035

ABSTRACT

The best understood mechanisms of omalizumab are that it neutralizes free IgE and down-regulates high-affinity IgE.Fc receptors (FcepsilonRI) on basophils and mast cells. It has been proposed that since complexes of IgE and omalizumab are accumulated to 5-10 times the basal levels of IgE, they may trap incoming allergens, contributing to omalizumab's effectiveness. In order to investigate the ability of IgE:omalizumab complexes in trapping allergens and inhibiting basophil activation in an in vitro reconstitution model, the ability of IgE:omalizumab complexes to tie up antigen and hence inhibit (a) antigen binding to IgE bound by FcepsilonRI, and (b) antigen-mediated activation of basophils, was examined. The free IgE was prepared by mixing different proportions of antigen-nonspecific IgE secreted by U266 cells and antigen-specific IgE, SE44 IgE, which recognizes a synthetic 15 a.a. peptide, R15K. The antigen was (R15K)(8)-ova, i.e. ovalbumin conjugated with an average of 8 copies of R15K per molecule. The solid-phase FcepsilonRI was a recombinant protein representing the extracellular portion of the alpha chain of the FcepsilonRI receptor complex. The model FcepsilonRI(+) basophilic cell line was RBL.SX-38, a rat basophilic leukemic line transfected with the genes for alpha, beta and gamma subunits of human FcepsilonRI. The results showed that the IgE:omalizumab complexes trapped increasing amounts of antigen with increasing (a) concentration of IgE, (b) proportion of antigen-specific IgE in total IgE, and (c) concentration of total immune complexes. Such trapping decreased the antigen-induced activation of FcepsilonRI(+) cells that had been pulsed with antigen-specific IgE, resulting in decreased mediator release. These results suggest that the rapidly accumulated IgE:omalizumab complexes in omalizumab-treated patients can capture allergens and consequently contribute to the pharmacological effects of omalizumab.


Subject(s)
Allergens/chemistry , Antibodies, Monoclonal/chemistry , Antigen-Antibody Complex/chemistry , Immunoglobulin E/chemistry , Animals , Antibodies, Anti-Idiotypic , Antibodies, Monoclonal, Humanized , Basophils/drug effects , Basophils/metabolism , Blotting, Western , Cell Line , Chromatography, Gel , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Immunoglobulin Fc Fragments/metabolism , Omalizumab , Rats , Staphylococcal Protein A/chemistry , beta-N-Acetylhexosaminidases/metabolism
20.
J Immunol ; 184(4): 1748-56, 2010 Feb 15.
Article in English | MEDLINE | ID: mdl-20083663

ABSTRACT

Membrane-bound IgE (mIgE) is part of the IgE-BCR and is essential for generating isotype-specific IgE responses. On mIgE(+) B cells, the membrane-bound epsilon-chain (mepsilon) exists predominantly in the long isoform, mepsilon(L), containing an extra 52 aa CepsilonmX domain between CH4 and the C-terminal membrane-anchoring segment; the short isoform of mepsilon, mepsilon(S), exists in minor proportions. CepsilonmX thus provides an attractive site for immunologic targeting of mIgE(+) B cells. In this study, we show that nine newly prepared CepsilonmX-specific mAbs, as well as the previously reported a20, bound to mIgE.Fc(L)-expressing CHO cells, while only 4B12 and 26H2 bound to mIgE.Fc(L)-expressing B cell line Ramos cells. The mAb 4B12 bound to the N-terminal part, 26H2 the middle part, and all others the C-terminal part of CepsilonmX. Expression of Igalpha and Igbeta on the mIgE.Fc(L)-CHO cells reduces the binding of a20 to CepsilonmX as compared with that of 4B12 and 26H2. The chimeric mAbs c4B12 and c26H2, when cross-linked by secondary antibodies, lysed mIgE.Fc(L)-Ramos cells by apoptosis through a BCR-dependent caspase pathway. Using PBMCs as the source of effector cells, c4B12 and c26H2 demonstrated Ab-dependent cellular cytotoxicity toward mIgE.Fc(L)-Ramos cells in a dose-dependent fashion. In cultures of PBMCs from atopic dermatitis patients, c4B12 and c26H2 inhibited the synthesis of IgE driven by anti-CD40 and IL-4. These results suggest that 4B12 and 26H2 and an immunogen using the peptide segments recognized by these mAbs are potentially useful for targeting mIgE(+) B cells to control IgE production.


Subject(s)
B-Lymphocyte Subsets/immunology , B-Lymphocyte Subsets/metabolism , Epitopes, B-Lymphocyte/genetics , Epitopes, B-Lymphocyte/metabolism , Gene Targeting , Immunoglobulin E/biosynthesis , Immunoglobulin epsilon-Chains/biosynthesis , Receptors, Antigen, B-Cell/metabolism , Amino Acid Sequence , Animals , Antibody-Dependent Cell Cytotoxicity/genetics , Apoptosis/genetics , Apoptosis/immunology , Binding Sites, Antibody/genetics , CHO Cells , Cell Line , Cell Line, Tumor , Clone Cells , Cricetinae , Cricetulus , Humans , Immunoglobulin E/genetics , Immunoglobulin E/metabolism , Immunoglobulin epsilon-Chains/metabolism , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Protein Isoforms/biosynthesis , Protein Isoforms/genetics , Protein Isoforms/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...